Advances in determination of Alzheimer's β-amyloid peptide

Yanli Zhou

College of Chemistry and Chemical Engineering- Shangqiu Normal University, China

Abstract

Alzheimer's disease (AD), as the most common progressive neurodegenerative disorder, is pathologically characterized by deposition of extracellular plaque composed of amyloid- β peptide (A β). Therefore, the development of reliable assays for A β (both monomers and oligomers) are important for the early differential diagnosis of dementia, predicting the progression of AD, as well as monitoring the effectiveness of novel anti-A β drugs for AD. Recently, our group has constructed several analytical assays for sensing A β (both monomers and oligomers): by using aptamer- and thioninemodified gold nanoparticles (aptamer-Au-Th) as the signing probe, we fabricated an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β -amyloid oligomers; based on the target-mediate aggreation of gold nanoparticle, we constructed a sensitive colorimetric assay for β -amyloid oligomers; based on the specific binding between Cu2+ and A β 1-40, we proposed a colorimetric assay as well as a fluorescent assay for A β 1-40 monomer.

Biography:-

Yanli Zhou has completed her PhD at the age of 27 years from the Technical Institute of Physics and Chemistry, Chinese Academy of Sciences. She is currently a professor at Shangqiu Normal University. She has published more than 40 papers in reputed journals.

Note: - This work is partly presented at International Webinar on Gene Therapy, May 29, 2021 as per GMT+1 Timings.